Alterity Therapeutics Limited American Depositary Shares (ATHE) Stock Price, Quote & AI Analysis
Live ATHE stock price, real-time charts, AI-powered analysis, technical analysis, earnings insights, and market sentiment for Alterity Therapeutics Limited American Depositary Shares.
TradeVae provides AI-driven analysis and real-time market intelligence for Alterity Therapeutics Limited American Depositary Shares (ATHE), including price action, technical indicators, earnings performance, analyst sentiment, and risk-aware market context.
AI Analysis
Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.
Generating AI analysis...
Alterity Therapeutics Limited American Depositary Shares's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.
Alterity Therapeutics Limited American Depositary Shares Overview
Company information
Company Overview
Alterity Therapeutics Ltd. engages in the business of research and development of therapeutic drugs designed to treat neurodegenerative diseases, focusing on Parkinsonian and other movement disorders. Its lead candidate, ATH434, is an oral small molecule drug designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.
Company Details
Technical Indicators
Key technical analysis metrics and indicators
Loading technical indicators...
Valuation Metrics
Key valuation ratios and comparisons
Loading valuation metrics...
Alterity Therapeutics Limited American Depositary Shares Earnings & Financial Statements
Earnings Calendar
Upcoming earnings dates and historical surprises
Loading earnings calendar...
Financial Statements
Income statements, balance sheets, and cash flow
Loading income statements...
Loading balance sheets...
Loading cash flow statements...